Mar 04,2020

AI-Pathway Companion Prostate Cancer from Siemens Healthineers Approved for Use in Europe as Medical Device

AI-Pathway Companion Prostate Cancer(2), a digital companion from Siemens Healthineers to support clinical decision-making, has recently received the CE mark for use in the clinical pathway of prostate cancer, the second most common cancer (after lung cancer) affecting males worldwide.(3) The conformity mark confirms that the application AI-Pathway Companion Prostate Cancer is CE-compliant in accordance with Directive 93/42/EEC and can therefore be marketed in the EU as a medical device.

REGULATORY CE MARK

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 24,2020

The Top Medical Specialties with the Biggest Potential in the Future

Cheaper genome sequencing and measuring blood biomarkers are speeding up this process. Companies like the spin-off venture of Illumina called GRAIL are developing fluid biopsies. These are blood tests able to detect all types of cancer from a very early stage. By being able to filter tumor cells from blood samples, doctors could soon diagnose and analyze tumors earlier and without costly surgery.

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 01,2020

Personalized Cancer Treatment, A Real Possibility?

What if a person with cancer could have personalized treatment based on information obtained from his or her blood plasma? What if the course of treatment was so precise, there’d be no more guessing as to whether it may or may not work? That possibility is about to become a reality through research currently being conducted by an Israeli company called Oncohost.

PRODUCT

#platform

#ai/software

View Analyst & Ambassador Comments
Go to original news
Mar 04,2020

Voluntis and Bristol-Myers Squibb to co-develop digital thrapeutics for oncology

Voluntis today announced a collaboration agreement to create and investigate digital therapeutic solutions that will support cancer patients. Leveraging Theraxium Oncology, Voluntis’ core platform for digital therapeutics in oncology, the collaboration will evaluate potential solutions that will support management of patient symptoms and remote monitoring by healthcare providers.

COLLABORATION PARTNERSHIP

#r&d

#dtx

#platform

View Analyst & Ambassador Comments
Go to original news
Mar 04,2020

Voluntis announces its new strategic roadmap

Voluntis recently inked two new partnerships related to its Theraxium Oncology platform with Novartis and Bristol-Myers Squibb[1]. In addition to these new collaborations, which complement the existing partnership with AstraZeneca, Voluntis is in discussion with several other pharmaceutical companies to improve patients’ experience with many types of cancer treatments.

View Analyst & Ambassador Comments
Go to original news
Mar 28,2020

Onco.com unveils teleconsultation service for cancer patients to get advice from oncologists

Onco.com, an internet aggregator for cancer care, has introduced a teleconsultation service to help cancer patients and care givers get advice from oncologists through a telephonic call or video conferencing. The recently launched teleconsultation service Call Onco offers support to patients to get their questions answered, with queries ranging from their current treatment status, diagnosis, and precautions against COVID-19. The teleconsultation will be 20 minutes long and will be scheduled within 24 hours.

PRODUCT

#telehealth

#platform

View Analyst & Ambassador Comments
Go to original news
Apr 01,2020

How to Rapidly Deploy a Telehealth High Risk Program: Engage Patients by Taking Your Program Virtual

COVID-19 has quickly altered society. It has changed workflows and processes and forced hospitals to discourage patients from coming in — to keep them safe and healthy. But there is an unintended consequence of that. Discouraging patients from seeing their provider may discourage them from doing things to prevent other serious, chronic conditions, like diabetes, hypertension — even cancer. It is the perfect time to shift the models of delivering important preventative care to a virtual model. In this blog post CancerIQ outlines various ways their clients have already done.

#telehealth

View Analyst & Ambassador Comments
Go to original news
Apr 23,2020

Paige adds $5M from Goldman Sachs to double down on AI-based cancer therapies

Paige, the Sloan-Kettering spinout that has been building an artificial intelligence platform to improve cancer pathology and subsequently use those insights to develop better drug therapies, has raised an additional $5 million in funding to continue its work commercialising its platform and expanding its research reach, while also getting FDA clearance to launch in hospitals in North America and Europe.

FUNDING SERIES B
View Analyst & Ambassador Comments
Go to original news
Apr 07,2020

Developing Personalized Strategies To Maximize Cancer Therapy Success

The number of cancer cases and fatalities across the globe continue to grow. Advances in our understanding of cancer pathophysiology, coupled with the ability to harness the human immune system, has enabled the development of precision therapies such as immunotherapy.

View Analyst & Ambassador Comments
Go to original news
May 11,2020

10 million € investment boosts Finnish capabilities in cancer immunotherapy

Cancer IO is a new cancer immunotherapy focused top-level collaborative research and innovation project that starts as a part of the Business Finland’s Personalized Health Program. This University of Helsinki coordinated project integrates immuno-oncology (IO) activities at the Universities of Helsinki and Turku, 3 University hospitals and one central hospital, 8 Finnish small or medium enterprises, several cancer patient organizations and the 9 largest IO-investing pharmaceutical companies. Kaiku Health takes part in this significant national project with its digital health intervention platform for detecting and managing immune-related adverse events during and after cancer immunotherapy treatments. The platform also includes first-of-its-kind algorithms for predictive toxicity management based on machine learning.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Subscribe to ONCOLOGY